Latest Conference Articles

Rethinking Initial Management of Patients With Brain Metastasis and HER2 Breast Cancer

June 6th 2011, 9:47am

ASCO Annual Meeting

Lapatinib and capecitabine is a reasonable approach in a well-informed patient with brain metastasis and HER2+ breast cancer

Two Studies Herald New Era in Melanoma Therapy

June 6th 2011, 7:07am

ASCO Annual Meeting

New treatment approaches that improve overall survival for patients with late-stage melanoma spotlighted

Three-Year Imatinib Regimen Delivers Optimal GIST Treatment

June 6th 2011, 6:47am

ASCO Annual Meeting

3 years of treatment with imatinib (Gleevec) after surgery in patients with high-risk GIST improved overall and recurrence-free survival

Pemetrexed Maintenance Improves Progression-Free Survival in Patients With NSCLC

June 6th 2011, 6:37am

ASCO Annual Meeting

Continuation maintenance with pemetrexed (Alimta) improves progression-free survival in patients with advanced nonsquamous non–small cell lung cancer

Dr. Wolchok Describes the Immunotherapy Ipilimumab

June 6th 2011, 6:26am

ASCO Annual Meeting

Dr. Wolchok from Memorial Sloan-Kettering Cancer Center Describes the Immunotherapy Ipilimumab

Dr. Kris on the Use of Genetic Testing in Lung Cancer

June 6th 2011, 5:38am

ASCO Annual Meeting

Dr. Kris From Memorial Sloan-Kettering Cancer Center on the Use of Genetic Testing in Lung Cancer

MEK and BRAF Therapy Combo Promising for Advanced Melanoma

June 5th 2011, 2:10pm

ASCO Annual Meeting

The combination of the MEK inhibitor GSK212 and the oral BRAF inhibitor GSK436 resulted in anti-tumor activity in patients with advanced melanoma

Dr. Virgo on Survivorship Care Training & Policies

June 5th 2011, 12:15pm

ASCO Annual Meeting

Dr. Katherine Virgo from the American Cancer Society Discusses Survivorship Care Training & Policies

Dr. Hoos on the Patients That Respond to Ipilimumab

June 5th 2011, 11:48am

ASCO Annual Meeting

Dr. Axel Hoos from Bristol Myers-Squib on the Patients That Respond to Ipilimumab

Dr. Chapman Describes the Side Effects of Vemurafenib

June 5th 2011, 11:43am

ASCO Annual Meeting

Dr. Paul Chapman from Memorial Sloan-Kettering Cancer Center Describes the Side Effects of Vemurafenib

Dr. Tsimberidou Discusses Improving Care

June 5th 2011, 11:23am

ASCO Annual Meeting

Apostolia M. Tsimberidou, MD, PhD, from MD Anderson Cancer Center discusses improving cancer care.

Dr. Cella on Patient Assessment Reference Scores

June 5th 2011, 11:07am

ASCO Annual Meeting

Dr. Cella from Northwestern University Feinberg School of Medicine on Patient Assessment Reference Scores

Genetic Testing Delivers Personalized Lung Cancer Therapy

June 5th 2011, 10:24am

ASCO Annual Meeting

Taking a page from breast cancer treatment, clinicians managing lung cancer patients can now detect mutations that drive the development of lung cancer

NKTR-102 Shows Promise in Phase II Trial

June 5th 2011, 9:58am

ASCO Annual Meeting

Metastatic breast cancer patients with demonstrated disease progression after taxane therapy face an uphill battle in fighting their disease.

Circulating Tumor Cells Show Promise as Surrogate for Survival in Prostate Cancer Trials

June 5th 2011, 6:31am

ASCO Annual Meeting

Prostate cancer research lacks surrogate biomarkers for survival that could hasten the study and approval of new medications.

Regional Radiation Therapy Improves Outcomes in Early Breast Cancer

June 5th 2011, 6:00am

ASCO Annual Meeting

Radiation therapy directed to the regional lymph nodes of women with early-stage breast cancer reduced distant disease recurrence

Amonafide Plus Cytarabine Fails To Meet Primary Endpoint

June 4th 2011, 10:08am

ASCO Annual Meeting

Amonafide+Cytarabine may not be effective for secondary acute myeloid leukemia, according to ACCEDE trial data

High-Dose Methotrexate Better for ALL

June 4th 2011, 9:54am

ASCO Annual Meeting

High doses of methotrexate increases EFS for children and young adults

Molecular Profiling Boosts Targeted Therapies in Phase I Trial

June 4th 2011, 9:14am

ASCO Annual Meeting

Matching patients with targeted therapies based on molecular profile results in superior clinical outcomes

Dr. Joensuu on the Imatinib for High-Risk GIST Trial

June 4th 2011, 7:51am

ASCO Annual Meeting

Dr. Heikki Joensuu from the Helsinki University Central Hospital Summarizes the Imatinib for High-Risk high-risk gastrointestinal stromal tumors (GIST) Trial